Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN1 | Q9GZT9 | 7/20 | 0.48 |
| ▸ | NR4A2 | P43354 | 2/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.48 |
| ▸ | ABL1 | P00519 | 1/20 | 0.45 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.45 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.43 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.43 |
| ▸ | TAS1R2 | Q8TE23 | 1/20 | 0.43 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3368085 | 0.89 | EGLN1 (0.53) | EGLN1NR4A2CYP2C9KCNH2 | |
| SCHEMBL3368247 | 0.88 | EGLN1 (0.52) | EGLN1NR4A2CYP2C9KCNH2 | |
| SCHEMBL3366289 | 0.83 | EGLN1 (0.56) | EGLN1NR4A2CYP2C9KCNH2DGAT1 | |
| SCHEMBL3368030 | 0.83 | NR4A2 (0.61) | EGLN1NR4A2CYP2C9KCNH2DGAT1 | |
| SCHEMBL3365539 | 0.83 | NR4A2 (0.53) | EGLN1NR4A2CYP2C9KCNH2DGAT1 | |
| SCHEMBL3367665 | 0.82 | NR4A2 (0.56) | EGLN1NR4A2CYP2C9KCNH2DGAT1 | |
| SCHEMBL2435156 | 0.81 | EGLN1 (0.50) | EGLN1NR4A2CYP2C9KCNH2DGAT1 | |
| SCHEMBL2432828 | 0.81 | CYP2C9 (0.50) | EGLN1NR4A2CYP2C9KCNH2DGAT1 | |
| SCHEMBL3784799 | 0.81 | EGLN1 (0.51) | EGLN1NR4A2CYP2C9KCNH2 | |
| SCHEMBL3366307 | 0.80 | EGLN1 (0.57) | EGLN1NR4A2CYP2C9KCNH2DGAT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2225241-B1 | Derivatives of N-phenyl-imidazo-(1,2-A)-pyridine-2-carboxamides, preparation thereof and therapeutic application thereof | SANOFI SA (FR) | 2011-09-14 | — | — | EP | claimed |
| US-20100317685-A1 | N-PHENYL-IMIDAZO[1,2-a]PYRIDINE-2-CARBOXAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION | SANOFI-AVENTIS (FR) | 2010-12-16 | — | — | US | claimed |
| EP-2225241-B1 | Derivatives of N-phenyl-imidazo-(1,2-A)-pyridine-2-carboxamides, preparation thereof and therapeutic application thereof | SANOFI SA (FR) | 2011-09-14 | — | — | EP | disclosed |
| US-20100317685-A1 | N-PHENYL-IMIDAZO[1,2-a]PYRIDINE-2-CARBOXAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION | SANOFI-AVENTIS (FR) | 2010-12-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100317685-A1 | N-PHENYL-IMIDAZO[1,2-a]PYRIDINE-2-CARBOXAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION | ARG2, IDH2, GLS | EGLN1 1093/4885NR4A2 376/4885CYP2C9 854/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.